0001193125-21-041124.txt : 20210212 0001193125-21-041124.hdr.sgml : 20210212 20210212143251 ACCESSION NUMBER: 0001193125-21-041124 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20210212 DATE AS OF CHANGE: 20210212 GROUP MEMBERS: ANNE-MARI PASTER GROUP MEMBERS: OMEGA FUND IV GP MANAGER, LTD. GROUP MEMBERS: OMEGA FUND IV GP, L.P. GROUP MEMBERS: OTELLO STAMPACCHIA SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ESSA Pharma Inc. CENTRAL INDEX KEY: 0001633932 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88939 FILM NUMBER: 21625840 BUSINESS ADDRESS: STREET 1: SUITE 720 STREET 2: 999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 BUSINESS PHONE: (778) 331-0962 MAIL ADDRESS: STREET 1: SUITE 720 STREET 2: 999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Omega Fund IV, L.P. CENTRAL INDEX KEY: 0001528382 IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 888 BOYLSTON ST., SUITE 1111 CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 617-502-6538 MAIL ADDRESS: STREET 1: 888 BOYLSTON ST., SUITE 1111 CITY: BOSTON STATE: MA ZIP: 02199 SC 13G/A 1 d102036dsc13ga.htm SC 13G/A SC 13G/A

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1

(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

(Amendment No. 3)*

 

 

Essa Pharma Inc.

(Name of Issuer)

Shares of Common Stock

(Title of Class of Securities)

29668H104

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

 

Rule 13d-1(b)

 

 

Rule 13d-1(c)

 

 

Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP NO. 29668H104    13 G    Page 2 of 10 Pages

 

  1    

  NAMES OF REPORTING PERSONS

 

  Omega Fund IV, L.P.

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒ (1)

 

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Cayman Islands

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

   5     

  SOLE VOTING POWER

 

  0

   6   

  SHARED VOTING POWER

 

  735,996

   7   

  SOLE DISPOSITIVE POWER

 

  0

   8   

  SHARED DISPOSITIVE POWER

 

  735,996

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  735,996

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  2.2% (2)

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  PN

 

(1)

This Schedule 13G is filed by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), Omega Fund IV GP Manager, Ltd. (“Omega Ltd”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”), (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

This percentage is based on 33,600,122 shares of Common Stock outstanding as of December 15, 2020 as set forth in the Issuer’s most recent Form 10-K for the period ending September 30, 2020, filed with the Securities and Exchange Commission on December 15, 2020 and (ii) immediately exercisable warrants to purchase 30,303 Common Stock held by Omega Fund.


CUSIP NO. 29668H104    13 G    Page 3 of 10 Pages

 

  1    

  NAMES OF REPORTING PERSONS

 

  Omega Fund IV GP, L.P.

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒ (1)

 

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Cayman Islands

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

   5     

  SOLE VOTING POWER

 

  0

   6   

  SHARED VOTING POWER

 

  735,996

   7   

  SOLE DISPOSITIVE POWER

 

  0

   8   

  SHARED DISPOSITIVE POWER

 

  735,996

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  735,996

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  2.2% (2)

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  PN

 

(1)

This Schedule 13G is filed by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), Omega Fund IV GP Manager, Ltd. (“Omega Ltd”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”), (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

This percentage is based on 33,600,122 shares of Common Stock outstanding as of December 15, 2020 as set forth in the Issuer’s most recent Form 10-K for the period ending September 30, 2020, filed with the Securities and Exchange Commission on December 15, 2020 and (ii) immediately exercisable warrants to purchase 30,303 Common Stock held by Omega Fund.


CUSIP NO. 29668H104    13 G    Page 4 of 10 Pages

 

  1    

  NAMES OF REPORTING PERSONS

 

  Omega Fund IV GP Manager, Ltd.

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒ (1)

 

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Cayman Islands

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

   5     

  SOLE VOTING POWER

 

  0

   6   

  SHARED VOTING POWER

 

  735,996

   7   

  SOLE DISPOSITIVE POWER

 

  0

   8   

  SHARED DISPOSITIVE POWER

 

  735,996

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  735,996

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  2.2% (2)

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  OO

 

(1)

This Schedule 13G is filed by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), Omega Fund IV GP Manager, Ltd. (“Omega Ltd”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”), (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

This percentage is based on 33,600,122 shares of Common Stock outstanding as of December 15, 2020 as set forth in the Issuer’s most recent Form 10-K for the period ending September 30, 2020, filed with the Securities and Exchange Commission on December 15, 2020 and (ii) immediately exercisable warrants to purchase 30,303 Common Stock held by Omega Fund.


CUSIP NO. 29668H104    13 G    Page 5 of 10 Pages

 

  1    

  NAMES OF REPORTING PERSONS

 

  Otello Stampacchia

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒ (1)

 

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Italy

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

   5     

  SOLE VOTING POWER

 

  42,000

   6   

  SHARED VOTING POWER

 

  735,996

   7   

  SOLE DISPOSITIVE POWER

 

  42,000

   8   

  SHARED DISPOSITIVE POWER

 

  735,996

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  777,996

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

  ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  2.3% (2)

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  IN

 

(1)

This Schedule 13G is filed by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), Omega Fund IV GP Manager, Ltd. (“Omega Ltd”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”), (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

This percentage is based on 33,600,122 shares of Common Stock outstanding as of December 15, 2020 as set forth in the Issuer’s most recent Form 10-K for the period ending September 30, 2020, filed with the Securities and Exchange Commission on December 15, 2020 and (ii) immediately exercisable warrants to purchase 30,303 Common Stock held by Omega Fund.


CUSIP NO. 29668H104    13 G    Page 6 of 10 Pages

 

  1    

  NAMES OF REPORTING PERSONS

 

  Anne-Mari Paster

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)  ☐        (b)  ☒(1)

 

  3  

  SEC USE ONLY

 

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  United States of America

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

   5     

  SOLE VOTING POWER

 

  0

   6   

  SHARED VOTING POWER

 

  735,996

   7   

  SOLE DISPOSITIVE POWER

 

  0

   8   

  SHARED DISPOSITIVE POWER

 

  735,996

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  735,996

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

      ☐

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  2.2% (2)

12  

  TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

  IN

 

(1)

This Schedule 13G is filed by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), Omega Fund IV GP Manager, Ltd. (“Omega Ltd”), Otello Stampacchia (“Stampacchia”), and Anne-Mari Paster (“Paster”), (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

This percentage is based on 33,600,122 shares of Common Stock outstanding as of December 15, 2020 as set forth in the Issuer’s most recent Form 10-K for the period ending September 30, 2020, filed with the Securities and Exchange Commission on December 15, 2020 and (ii) immediately exercisable warrants to purchase 30,303 Common Stock held by Omega Fund.


CUSIP NO. 29668H104    13 G    Page 7 of 10 Pages

 

Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock (“Common Stock”), of Essa Pharma Inc. (the “Issuer”).

 

Item 1(a)

Name of Issuer:

Essa Pharma Inc. (the “Issuer”)

 

Item 1(b)

Address of Issuer’s principal executive offices:

Essa Pharma Inc.

999 West Broadway, Suite 720

Vancouver, British Columbia

Canada V5Z 1K5

 

Items 2(a)

Name of Reporting Persons filing:

Omega Fund IV, L.P. (“Omega Fund”)

Omega Fund IV GP, L.P. (“Omega GP”)

Omega Fund IV GP Manager, Ltd. (“Omega Ltd”)

Otello Stampacchia (“Stampacchia”)

Anne-Mari Paster (“Paster”)

 

Item 2(b)

Address or principal business office or, if none, residence:

The address of the principal business office of Omega Fund, Omega GP, Omega Ltd, Stampacchia, and Paster, is c/o Omega Fund Management, LLC, 888 Boylston Street, Suite 1111, Boston, MA 02199.

 

Item 2(c)

Citizenship:

 

                      

Name

  

Citizenship or Place of Organization

  Omega Fund    Cayman Islands
  Omega GP    Cayman Islands
  Omega Ltd.    Cayman Islands
  Stampacchia    Italy
  Paster    United States of America

 

Item 2(d)

Title of class of securities:

Shares of Common Stock

 

Item 2(e)

CUSIP No.:

29668H104

 

Item 3

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

Not applicable.

 

Item 4

Ownership

The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2020.

 


CUSIP NO. 29668H104    13 G    Page 8 of 10 Pages

 

Reporting Persons

   Shares of
Common
Stock Held
Directly
     Sole
Voting
Power
     Shared
Voting
Power
     Sole
Dispositive
Power
     Shared
Dispositive
Power
     Beneficial
Ownership
     Percentage
of Class

(1)
 

Omega Fund(2)(3)

     735,996        0        735,996        0        735,996        735,996        2.2

Omega GP(2)(3)

     0        0        735,996        0        735,996        735,996        2.2

Omega Ltd(2)(3)

     0        0        735,996        0        735,996        735,996        2.2

Stampacchia(2)(3)

     0        42,000        735,996        42,000        735,996        777,996        2.3

Paster(2)(3)

     0        0        735,996        0        735,996        735,996        2.2

 

(1)

This percentage is based on 33,600,122 shares of Common Stock outstanding as of December 15, 2020 as set forth in the Issuer’s most recent Form 10-K for the period ending September 30, 2020, filed with the Securities and Exchange Commission on December 15, 2020 and (ii) immediately exercisable warrants to purchase 30,303 Common Stock held by Omega Fund.

(2)

Omega Fund owns 705,693 shares and an immediately exercisable warrant to purchase 30,303 shares of Common Stock. Stampacchia owns fully vested options to purchase 42,000 shares of Common Stock which he holds of record. Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund, and each of Omega GP and Omega Ltd may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Paster are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares of the Issuer’s Common Stock held by Omega Fund except to the extent of his, her or its pecuniary interest therein.

(3)

The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

Item 5

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒.

 

Item 6

Ownership of More than Five Percent on Behalf of Another Person

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

 

Item 8

Identification and Classification of Members of the Group

Not applicable.

 

Item 9

Notice of Dissolution of Group

Not applicable.

 

Item 10

Certifications

Not applicable.


CUSIP NO. 29668H104    13 G    Page 9 of 10 Pages

 

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated:   February 12, 2021
OMEGA FUND IV, L.P.
BY:   Omega Fund IV GP, L.P.
ITS:   GENERAL PARTNER
BY:   Omega Fund IV G.P. Manager, Ltd.
ITS:   GENERAL PARTNER
By:  

/s/ * Deirdre A. Cunnane, as Attorney-in-Fact

Name:   Anne-Mari Paster
Title:   Director
OMEGA FUND IV GP, L.P.
BY:   Omega Fund IV G.P. Manager, Ltd.
ITS:   GENERAL PARTNER
By:  

/s/ * Deirdre A. Cunnane, as Attorney-in-Fact

Name:   Anne-Mari Paster
Title:   Director
OMEGA FUND IV G.P. MANAGER, LTD.
By:  

/s/ * Deirdre A. Cunnane, as Attorney-in-Fact

Name:   Anne-Mari Paster
Title:   Director

/s/ * Deirdre A. Cunnane, as Attorney-in-Fact

Otello Stampacchia

/s/ * Deirdre A. Cunnane, as Attorney-in-Fact

Anne-Mari Paster


CUSIP NO. 29668H104    13 G    Page 10 of 10 Pages

 

Exhibit(s):

Exhibit 99.1: Joint Filing Statement

Exhibit 99.2: Power of Attorney

 

EX-99.1 2 d102036dex991.htm EX-99.1 EX-99.1
CUSIP No. 29668H104    13G    Exhibit 99.1

AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Essa Pharma Inc.

 

Dated:   February 12, 2021
OMEGA FUND IV, L.P.
BY:   Omega Fund IV GP, L.P.
ITS:   GENERAL PARTNER
BY:   Omega Fund IV G.P. Manager, Ltd.
ITS:   GENERAL PARTNER
By:  

/s/ * Deirdre A. Cunnane, as Attorney-in-Fact

Name: Anne-Mari Paster
Title: Director
OMEGA FUND IV GP, L.P.
BY:   Omega Fund IV G.P. Manager, Ltd.
ITS:   GENERAL PARTNER
By:  

/s/ * Deirdre A. Cunnane, as Attorney-in-Fact

Name: Anne-Mari Paster
Title: Director
OMEGA FUND IV G.P. MANAGER, LTD.
By:  

/s/ * Deirdre A. Cunnane, as Attorney-in-Fact

Name: Anne-Mari Paster
Title: Director

/s/ * Deirdre A. Cunnane, as Attorney-in-Fact

Otello Stampacchia

/s/ * Deirdre A. Cunnane, as Attorney-in-Fact

Anne-Mari Paster

 

EX-99.2 3 d102036dex992.htm EX-99.2 EX-99.2
CUSIP No. 29668H104    13G    Exhibit 99.2

POWER OF ATTORNEY

Know all by these presents, that each of the undersigned hereby constitutes and appoints each other undersigned, such person’s true and lawful attorney-in-fact, to:

 

  (1)

execute for and on behalf of each of such person Forms 3, 4, and 5 and Schedules 13D or 13G, as appropriate, and any required amendments thereto (collectively, the “Reports”), with respect to their current or future beneficial ownership of securities of any public company, in accordance with Section 13(d) and/or Section 16(a) of the Securities Exchange Act of 1934, as amended, and the respective rules (including Rule 13d-1) promulgated thereunder;

 

  (2)

do and perform any and all acts for and on behalf of such person which may be necessary or desirable to complete and execute any such Report and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

 

  (3)

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of an attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, such person, it being understood that the documents executed by an attorney-in-fact on behalf of such person pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

Each of the undersigned hereby grants to each attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. Each of the undersigned hereby ratifies and confirms each Report that has been signed by any other undersigned prior to the date hereof. Each of the undersigned acknowledges that each foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigneds’ responsibilities to comply with Section 13(d) or Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned are no longer required to file Reports with respect to the undersigneds’ current or future holdings of and transactions in securities issued by any public company, unless earlier revoked by the undersigned in a signed writing delivered to each foregoing attorney-in-fact.

[The remainder of this page is intentionally left blank.]


CUSIP No. 29668H104    13G   

 

IN WITNESS WHEREOF, the undersigned have caused this Power of Attorney to be executed as of dates set forth opposite their names.

 

/s/ Otello Stampacchia

                   Dated: February 12, 2021
Otello Stampacchia      

/s/ Claudio Nessi

      Dated: February 12, 2021
Claudio Nessi      

/s/ Anne-Mari Paster

      Dated: February 12, 2021
Anne-Mari Paster      

/s/ Deirdre A. Cunnane

      Dated: February 12, 2021
Deirdre A. Cunnane